Watch mergers and acquisitions ｜ Nanxin Pharmaceutical: High vision, low hands speed

Recently, Nanxin Pharmaceutical adjustment acquisition of Xingmeng biological solutions has changed from 100 %cash to the acquisition of cash to increase capital increase and cash.

In October 2020, Nanxin Pharmaceutical, which was only 1 billion in the pocket, wanted to exchange valuation bubbles at the stock price bubble, while taking advantage of more than 50 yuan/share, a fixed increase at a premium of 472 times and nearly 2.6 billion yuan was acquired.Biotech Xingmeng Pharmaceutical.It is impossible for the new shares to approve the rhythm of the approval of the mergers and acquisitions.

The Hong Kong market is available for selling new shares, and the mainland market is impossible. Nanxin Pharmaceutical has an eye. However, there is no approved window eye. In the end, the best merger and acquisition period was missed.

(Oriental Gao Sheng Li Jiamin/Wen)

- END -